tiprankstipranks
Trending News
More News >

Larimar Therapeutics selloff a buying opportunity, says Citi

Citi views yesterday’s selloff in shares of Larimar Therapeutics (LRMR) as a buying opportunity. Larimar announced that the FDA recommended the safety database for nomlabofusp include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose, the analyst tells investors in a research note. The firm says that with full FDA alignment in hand, Larimar has a clear path to application submission, which is now guided for Q2 of 2026 versus the second half of 2025 previously, to allow for additional time to collect one year of safety follow-up for patients. Citi keeps a Buy rating on the shares with a $14 price target

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1